Overview Dividends

(NEO) NeoGenomics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US64049M2098

Oncology Testing, Genetic Analysis, Molecular Diagnostics, Flow Cytometry, Pharmacogenomics

EPS (Earnings per Share)

EPS Growth (3y CAGR): 18.86%
EPS Trend (3y Corr): 22.4%

Last SUE: 0.10σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 11.65%
Revenue Trend (3y Corr): 98.0%

Last SUE: 0.91σ
Qual. Beats: 1

Risk via 10d forecast
Volatility	65.5%
Value at Risk 5%th	87.5%
Relative Tail Risk	-18.89%

Reward TTM
Sharpe Ratio	-0.09
Alpha	-48.57

Character TTM
Hurst Exponent	0.434
Beta	1.225
Beta Downside	0.742

Drawdowns 3y
Max DD	76.65%
Mean DD	31.04%
Median DD	28.08%

Description: NEO NeoGenomics November 18, 2025

NeoGenomics, Inc. (NASDAQ: NEO) runs a network of cancer-focused testing laboratories across the United States and the United Kingdom, organized into two reporting segments: Clinical Services and Advanced Diagnostics. The firm provides a broad menu of pathology-related tests-including cytogenetics, FISH, flow cytometry, immunohistochemistry with digital imaging, and molecular DNA/RNA analyses-to hospitals, academic centers, pathologists, oncologists, pharmaceutical companies, and other clinical labs.

Key recent metrics suggest the business is scaling: FY 2023 revenue reached approximately $620 million, up roughly 12 % year-over-year, while adjusted EBITDA margin hovered near 15 %, reflecting both volume growth and operational leverage. The oncology diagnostics market is projected to expand at a CAGR of 7-9 % through 2030, driven by increasing cancer incidence, the shift toward personalized therapy, and expanding payer coverage for molecular testing. However, NeoGenomics remains exposed to reimbursement volatility and competitive pressure from larger players such as Quest Diagnostics and Labcorp, which could compress margins if payer policies tighten.

For a deeper, data-driven view of NeoGenomics’ valuation dynamics, you may find it useful to explore the analysis on ValueRay, where the platform aggregates recent earnings trends and sector benchmarks.

NEO Stock Overview

Market Cap in USD	1,338m
Sub-Industry	Health Care Services
IPO / Inception	1999-11-02
Return 12m vs S&P 500	-39.0%
Analyst Rating	4.0 of 5

NEO Dividends

Currently no dividends paid

NEO Growth Ratios

Metric	Value
CAGR 3y	0.79%
CAGR/Max DD Calmar Ratio	0.01
CAGR/Mean DD Pain Ratio	0.03
Current Volume	2986.9k
Average Volume	2826.6k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-113.5m TTM) > 0 and > 6% of Revenue (6% = 42.5m TTM)

FCFTA -0.01 (>2.0%) and ΔFCFTA 0.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 40.13% (prev 45.62%; Δ -5.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.01 (>3.0%) and CFO 13.7m > Net Income -113.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.91 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (25.6m) change vs 12m ago 0.76% (target <= -2.0% for YES)

Gross Margin 43.46% (prev 43.54%; Δ -0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 47.03% (prev 39.25%; Δ 7.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -22.98 (EBITDA TTM -40.2m / Interest Expense TTM 4.78m) >= 6 (WARN >= 3)

Altman Z'' -1.15

(A) 0.21 = (Total Current Assets 382.5m - Total Current Liabilities 97.9m) / Total Assets 1.37b

(B) -0.31 = Retained Earnings (Balance) -423.9m / Total Assets 1.37b

(D) -0.97 = Book Value of Equity -423.7m / Total Liabilities 438.6m

Total Rating: -1.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 38.24

1. Piotroski 1.0pt = -4.0

2. FCF Yield -1.08% = -0.54

3. FCF Margin -2.40% = -0.90

4. Debt/Equity 0.49 = 2.38

5. Debt/Ebitda -6.12 = -2.50

6. ROIC - WACC (= -16.70)% = -12.50

7. RoE -13.03% = -2.17

8. Rev. Trend 98.05% = 7.35

9. EPS Trend 22.38% = 1.12

What is the price of NEO shares?

As of November 19, 2025, the stock is trading at USD 10.41 with a total of 2,986,905 shares traded.
Over the past week, the price has changed by -0.10%, over one month by -1.70%, over three months by +66.83% and over the past year by -30.65%.

Is NEO a buy, sell or hold?

NeoGenomics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy NEO.

Strong Buy: 6
Buy: 2
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the NEO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	13.1	25.5%
Analysts Target Price	13.1	25.5%
ValueRay Target Price	11.3	8.1%

NEO Fundamental Data Overview November 16, 2025

Market Cap USD = 1.34b (1.34b USD * 1.0 USD.USD)
P/E Forward = 222.2222
P/S = 1.8866
P/B = 1.5442
P/EG = 3.02
Beta = 1.616
Revenue TTM = 709.2m USD
EBIT TTM = -109.8m USD
EBITDA TTM = -40.2m USD
Long Term Debt = 341.5m USD (from longTermDebt, last quarter)
Short Term Debt = 4.51m USD (from shortTermDebt, last quarter)
Debt = 410.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 246.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.58b USD (1.34b + Debt 410.3m - CCE 164.1m)
Interest Coverage Ratio = -22.98 (Ebit TTM -109.8m / Interest Expense TTM 4.78m)
FCF Yield = -1.08% (FCF TTM -17.0m / Enterprise Value 1.58b)
FCF Margin = -2.40% (FCF TTM -17.0m / Revenue TTM 709.2m)
Net Margin = -16.00% (Net Income TTM -113.5m / Revenue TTM 709.2m)
Gross Margin = 43.46% ((Revenue TTM 709.2m - Cost of Revenue TTM 401.0m) / Revenue TTM)
Gross Margin QoQ = 42.84% (prev 42.61%)
Tobins Q-Ratio = 1.15 (Enterprise Value 1.58b / Total Assets 1.37b)
Interest Expense / Debt = 0.15% (Interest Expense 603.0k / Debt 410.3m)
Taxrate = -2.80% (negative due to tax credits) (740.0k / -26.4m)
NOPAT = -112.9m (EBIT -109.8m * (1 - -2.80%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.91 (Total Current Assets 382.5m / Total Current Liabilities 97.9m)
Debt / Equity = 0.49 (Debt 410.3m / totalStockholderEquity, last quarter 838.3m)
Debt / EBITDA = -6.12 (negative EBITDA) (Net Debt 246.2m / EBITDA -40.2m)
Debt / FCF = -14.44 (negative FCF - burning cash) (Net Debt 246.2m / FCF TTM -17.0m)
Total Stockholder Equity = 870.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.25% (Net Income -113.5m / Total Assets 1.37b)
RoE = -13.03% (Net Income TTM -113.5m / Total Stockholder Equity 870.7m)
RoCE = -9.06% (EBIT -109.8m / Capital Employed (Equity 870.7m + L.T.Debt 341.5m))
RoIC = -8.60% (negative operating profit) (NOPAT -112.9m / Invested Capital 1.31b)
WACC = 8.09% (E(1.34b)/V(1.75b) * Re(10.53%) + D(410.3m)/V(1.75b) * Rd(0.15%) * (1-Tc(-0.03)))
Discount Rate = 10.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.79%
Fair Price DCF = unknown (Cash Flow -17.0m)
EPS Correlation: 22.38 | EPS CAGR: 18.86% | SUE: 0.10 | # QB: 0
Revenue Correlation: 98.05 | Revenue CAGR: 11.65% | SUE: 0.91 | # QB: 1

Additional Sources for NEO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle